6533b82ffe1ef96bd129594c

RESEARCH PRODUCT

Exploratory outcome analyses according to stage and residual disease in the ICON7 trial of front-line carboplatin/paclitaxel (CP) ± bevacizumab (BEV) for ovarian cancer (OC).

Amit M. OzaMahesh M K ParmarEric Pujade-lauraineMonique BertrandJonathan A. LedermannLada MitchellNana ScottoGunnar B. KristensenRichard KaplanEmma KentAntonio González-martínPhilip BealeAndrew C. EmbletonAndres Cervantes-ruiperezJacobus PfistererTimothy J. Perren

subject

OncologyCancer Researchmedicine.medical_specialtyBevacizumabbusiness.industrydigestive oral and skin physiologyFront lineDiseasemedicine.diseaseCarboplatin/paclitaxelSurgeryOncologyInternal medicineMedicineSingle agentIn patientStage (cooking)businessOvarian cancermedicine.drug

description

5548 Background: In ICON7, progression-free survival (PFS) was significantly improved in patients (pts) receiving BEV with front-line CP and continued as a single agent [Perren 2011] but no overall...

https://doi.org/10.1200/jco.2015.33.15_suppl.5548